Company:  URIGEN PHARMACEUTICALS, I ...
Form Type:  10-K
Filing Date:  8/10/2012 
CIK:  0000932352 
Address:  501 SILVERSIDE ROAD PMB#95 
City, State, Zip:  WILMINGTON, Delaware 19809 
Telephone:  (925) 280-2861 
Fiscal Year:  06/30 
Description of Business
We specialize in the development of innovative products for patients with urological ailments including, specifically, the development of innovative products for amelioration of Bladder Pain Syndrome/Interstitial Cystitis ("BPS" or "BPS/IC"). Urology represents a specialty pharmaceutical market of, according to the American Urology Association (the "AUA"), approximately 10,000 physicians in the United States. Urologists treat a variety of ailments of the urinary tract including urinary tract infections, bladder cancer, overactive bladder, urgency and incontinence and interstitial cystitis, a subset of BPS. Many of these indications, we believe, represent significant, underserved therapeutic market opportunities. Over the next several years, we believe, a number of key demographic and technological factors should accelerate growth in the market for medical therapies to treat urological disorders, particularly in our product categories.
Register for a Free Trial and access this filing in:     
  FORM 10-K
    PART I
      ITEM 1. DESCRIPTION OF BUSINESS
      ITEM 1A. RISK FACTORS
      ITEM 1B. UNRESOLVED STAFF COMMENTS
      ITEM 2. PROPERTIES
      ITEM 3. LEGAL PROCEEDINGS
      ITEM 4. MINE SAFETY DISCLOSURES
    PART II
      ITEM 5. MARKET FOR COMMON EQUITY, RELATED ...
      ITEM 6. SELECTED FINANCIAL DATA
      ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF ...
        Results of Operations
        Liquidity and Capital Resources
      ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ...
      ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
      ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ...
      ITEM 9A. CONTROLS AND PROCEDURES
      ITEM 9B. OTHER INFORMATION
    PART III
      ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND ...
        NAME AND TITLE
      ITEM 11. EXECUTIVE COMPENSATION
        COMPENSATION TABLE
      ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL ...
        BENEFICIAL OWNERS
      ITEM 13. CERTAIN RELATIONSHIPS AND RELATED ...
      ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
    PART IV
      ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
    SIGNATURES
    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
    BALANCE SHEET
    INCOME STATEMENT
    STOCKHOLDERS EQUITY
    STOCKHOLDERS EQUITY
    STOCKHOLDERS EQUITY
    STOCKHOLDERS EQUITY
    STOCKHOLDERS EQUITY
    CASH FLOW
    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
  EXHIBIT 10.27
  EXHIBIT 10.31
  EXHIBIT 10.35
  EXHIBIT 21.1
  EXHIBIT 23.1
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  EXHIBIT 31.1
    Certification of Principal Executive Officer and Principal ...
  EXHIBIT 32.1
    Certification of Principal Executive Officer and Principal ...